© Reuters.
In a recent move, Lathan Corinna, a director at Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), has made a series of share purchases, signaling confidence in the company’s future prospects. Over a series of transactions, Corinna acquired a total of $15,477 worth of shares at prices ranging from $0.9494 to $1.25.
The first purchase, made on August 10, 2023, involved 4,201 shares at $1.25 each. This was followed by an acquisition of 5,500 shares on August 23 at a lower price of $0.9494 per share. A subsequent purchase on November 2 saw an additional 4,032 shares bought at $1.2412 each.
These transactions have increased Corinna’s stake in the company significantly. According to the SEC filing, which includes footnotes indicating the ownership of 67,392 unvested Restricted Stock Units (RSUs), the director’s total holdings have risen to 147,990 shares following these transactions.
Investors often view insider purchases as a positive sign, as they may indicate that the company’s leadership has a bullish outlook on the stock’s value and the company’s performance. For Ekso Bionics, a company specialized in general industrial machinery and equipment, this could be an encouraging sign for shareholders and potential investors alike.
As the company continues its operations, stakeholders will be keeping a close eye on further insider transactions, which can offer valuable insights into the perspectives of those who know the company best.
InvestingPro Insights
Following the recent insider purchases by Lathan Corinna, a director at Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), market participants may be seeking additional data to gauge the company’s financial health and future prospects. InvestingPro provides a deeper dive into the company’s performance and outlook with real-time data and analytics.
One of the most notable InvestingPro Data metrics is the Revenue Growth for Ekso Bionics in the last twelve months as of Q4 2023, which stands at an impressive 41.57%. This robust growth rate may underpin the director’s confidence in the company’s future prospects. The company also boasts a Gross Profit Margin of 49.67% in the same period, indicating a strong ability to control costs relative to revenue.
However, the company’s Operating Income Margin for the last twelve months as of Q4 2023 is reported at -82.67%, reflecting challenges in translating gross profits into operational earnings. Additionally, the company’s stock price has experienced significant volatility, with a 6-month total return of 67.29%, but a YTD price total return of -46.0% as of the referenced date.
InvestingPro Tips highlight that Ekso Bionics is expected to grow its net income this year, which aligns with the director’s recent share purchases. On the flip side, the company has been quickly burning through cash, which could be a point of concern for investors. Moreover, with a current market cap of 24.17M USD and a Price to Book ratio of 2.0, the company’s valuation metrics offer additional layers for potential investors to consider.
For those intrigued by the insider transactions and seeking a comprehensive analysis of Ekso Bionics, InvestingPro offers additional insights. There are 11 more InvestingPro Tips available for Ekso Bionics, which can be accessed by visiting https://www.investing.com/pro/EKSO. To get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, use the coupon code PRONEWS24.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
